Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

- PMLiVE

Merck & Co fails to block generic Januvia in India

Court says Glenmark can sell cheap copy of diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links